oral selective ER degrader and antagonist

in Ph. IIb studies for ER+ breast cancer

from ligand-based design and opt.

J. Med. Chem., Sep. 29, 2020

AstraZeneca, Cambridge, UK / Waltham, MA

Structure of AZD9833, a selective oestrogen receptor degrader (SERD)

AZD9833 is a potent, orally available selective estrogen receptor degrader (SERD) and antagonist in development for breast cancer. The only approved SERD is the widely used fulvestrant, which is given…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: